Equity-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement [Abstract]

Summary of details regarding stock option activity

The following table summarizes stock option activity for the three months ended March 31, 2020:

	2019	2007	Lumara Health	Inducement
	Plan	Plan	2013 Plan	Grants	Total
Outstanding at December 31, 2019	472,412	2,585,466	131,775	696,164	3,885,817
Granted	228,650	—	—	—	228,650
Exercised	—	—	—	—	—
Expired or terminated	(35,600)	(113,530)	(2,988)	(32,598)	(184,716)
Outstanding at March 31, 2020	665,462	2,471,936	128,787	663,566	3,929,751

Summary of details regarding restricted stock activity

The following table summarizes RSU activity for the three months ended March 31, 2020:

	2019	2007	Lumara Health	Inducement
	Plan	Plan	2013 Plan	Grants	Total
Outstanding at December 31, 2019	128,742	1,407,305	2,167	41,223	1,579,437
Granted	647,029	—	—	—	647,029
Vested	—	(402,993)	(366)	(2,001)	(405,360)
Expired or terminated	(6,200)	(204,161)	—	(3,001)	(213,362)
Outstanding at March 31, 2020	769,571	800,151	1,801	36,221	1,607,744

Schedule of equity-based compensation expense

Equity-based compensation expense for the three months ended March 31, 2020 and 2019 consisted of the following (in thousands):

	Three Months Ended March 31,
	2020		2019
Cost of product sales	$	203	$	202
Research and development	70		680
Selling, general and administrative	3,512		3,325
Total equity-based compensation expense	3,785		4,207
Income tax effect	—		—
After-tax effect of equity-based compensation expense	$	3,785	$	4,207